These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 29454849)

  • 1. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).
    Reinwald M; Silva JT; Mueller NJ; Fortún J; Garzoni C; de Fijter JW; Fernández-Ruiz M; Grossi P; Aguado JM
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S53-S70. PubMed ID: 29454849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways).
    Aguilar-Company J; Fernández-Ruiz M; García-Campelo R; Garrido-Castro AC; Ruiz-Camps I
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S41-S52. PubMed ID: 29426804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4).
    Drgona L; Gudiol C; Lanini S; Salzberger B; Ippolito G; Mikulska M
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S83-S94. PubMed ID: 29572070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).
    Redelman-Sidi G; Michielin O; Cervera C; Ribi C; Aguado JM; Fernández-Ruiz M; Manuel O
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2(Suppl 2):S95-S107. PubMed ID: 29427804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).
    Baddley JW; Cantini F; Goletti D; Gómez-Reino JJ; Mylonakis E; San-Juan R; Fernández-Ruiz M; Torre-Cisneros J
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S10-S20. PubMed ID: 29459143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52).
    Mikulska M; Lanini S; Gudiol C; Drgona L; Ippolito G; Fernández-Ruiz M; Salzberger B
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S71-S82. PubMed ID: 29447988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).
    Winthrop KL; Mariette X; Silva JT; Benamu E; Calabrese LH; Dumusc A; Smolen JS; Aguado JM; Fernández-Ruiz M
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S21-S40. PubMed ID: 29447987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Introduction).
    Fernández-Ruiz M; Meije Y; Manuel O; Akan H; Carratalà J; Aguado JM; Delaloye J
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S2-S9. PubMed ID: 29427801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Editorial for ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective.
    Aguado JM; Manuel O
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S1. PubMed ID: 29803289
    [No Abstract]   [Full Text] [Related]  

  • 10. Risk of infection associated with targeted therapies for solid organ and hematological malignancies.
    Ruiz-Camps I; Aguilar-Company J
    Ther Adv Infect Dis; 2021; 8():2049936121989548. PubMed ID: 33680453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature.
    Knoll BM; Seiter K
    Infection; 2018 Jun; 46(3):409-418. PubMed ID: 29388066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
    Maddocks K; Jones JA
    Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Pathways: Increased Susceptibility to Infection Is a Complication of mTOR Inhibitor Use in Cancer Therapy.
    Eiden AM; Zhang S; Gary JM; Simmons JK; Mock BA
    Clin Cancer Res; 2016 Jan; 22(2):277-83. PubMed ID: 26607598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: 'ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies' by Mikulska et al.
    Wijetilleka S; Jayne D; Mukhtyar C; Karim MY
    Clin Microbiol Infect; 2019 Apr; 25(4):531-532. PubMed ID: 30594651
    [No Abstract]   [Full Text] [Related]  

  • 17. Infectious Complications of Tyrosine Kinase Inhibitors in Hematological Malignancies.
    Kin A; Schiffer CA
    Infect Dis Clin North Am; 2020 Jun; 34(2):245-256. PubMed ID: 32444010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
    Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
    Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.
    Chamilos G; Lionakis MS; Kontoyiannis DP
    Clin Infect Dis; 2018 Jan; 66(1):140-148. PubMed ID: 29029010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
    Robak T; Robak P
    Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.